These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 28088581)

  • 1. A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis.
    Boursier J; de Ledinghen V; Leroy V; Anty R; Francque S; Salmon D; Lannes A; Bertrais S; Oberti F; Fouchard-Hubert I; Calès P
    J Hepatol; 2017 Jun; 66(6):1158-1165. PubMed ID: 28088581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD.
    Boursier J; Guillaume M; Leroy V; Irlès M; Roux M; Lannes A; Foucher J; Zuberbuhler F; Delabaudière C; Barthelon J; Michalak S; Hiriart JB; Peron JM; Gerster T; Le Bail B; Riou J; Hunault G; Merrouche W; Oberti F; Pelade L; Fouchard I; Bureau C; Calès P; de Ledinghen V
    J Hepatol; 2019 Aug; 71(2):389-396. PubMed ID: 31102719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simple blood fibrosis tests reduce unnecessary referrals for specialized evaluations of liver fibrosis in NAFLD and ALD patients.
    Broussier T; Lannes A; Zuberbuhler F; Oberti F; Fouchard I; Hunault G; Cales P; Boursier J
    Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):349-355. PubMed ID: 31422033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events.
    Boursier J; Hagström H; Ekstedt M; Moreau C; Bonacci M; Cure S; Ampuero J; Nasr P; Tallab L; Canivet CM; Kechagias S; Sánchez Y; Dincuff E; Lucena A; Roux M; Riou J; Trylesinski A; Romero-Gomez M
    J Hepatol; 2022 May; 76(5):1013-1020. PubMed ID: 35063601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of the combined FibroMeter vibration-controlled transient elastography algorithm in Chinese patients with non-alcoholic fatty liver disease.
    Loong TC; Wei JL; Leung JC; Wong GL; Shu SS; Chim AM; Chan AW; Choi PC; Tse YK; Chan HL; Wong VW
    J Gastroenterol Hepatol; 2017 Jul; 32(7):1363-1369. PubMed ID: 27936280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of eLIFT for Non-invasive Assessment of Liver fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Virus Infection.
    Li Q; Lu C; Li W; Huang Y; Chen L
    Sci Rep; 2017 Jul; 7(1):5429. PubMed ID: 28710435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Easy Liver Fibrosis Test (eLIFT) for predicting advanced liver fibrosis in patients with chronic hepatitis B.
    Wang J; Chen Z; Yan X; Yang Y; Liu Y; Chen Y; Jia B; Xia J; Xiong Y; Zhang Z; Ding W; Huang R; Wu C
    Discov Med; 2019 Sep; 28(153):149-158. PubMed ID: 31926586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reply to: "Pitfalls in the non-invasive assessment of liver fibrosis with eLIFT-FM
    Boursier J; de Ledinghen V; Leroy V; Calès P
    J Hepatol; 2018 Mar; 68(3):605-606. PubMed ID: 28987517
    [No Abstract]   [Full Text] [Related]  

  • 9. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease.
    Boursier J; Vergniol J; Guillet A; Hiriart JB; Lannes A; Le Bail B; Michalak S; Chermak F; Bertrais S; Foucher J; Oberti F; Charbonnier M; Fouchard-Hubert I; Rousselet MC; Calès P; de Lédinghen V
    J Hepatol; 2016 Sep; 65(3):570-8. PubMed ID: 27151181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis.
    Boursier J; Vergniol J; Sawadogo A; Dakka T; Michalak S; Gallois Y; Le Tallec V; Oberti F; Fouchard-Hubert I; Dib N; Rousselet MC; Konaté A; Amrani N; de Ledinghen V; Calès P
    Liver Int; 2009 Nov; 29(10):1507-15. PubMed ID: 19725892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic usefulness of FibroMeter VCTE for hepatic fibrosis in patients with nonalcoholic fatty liver disease.
    Dincses E; Yilmaz Y
    Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1149-53. PubMed ID: 26049712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining routine markers improves the accuracy of transient elastography for hepatitis B cirrhosis detection.
    Liang XE; Dai L; Yang SL; Zhong CX; Peng J; Zhu YF; Chen YP; Hou JL
    Dig Liver Dis; 2016 May; 48(5):512-518. PubMed ID: 26965782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD.
    Canivet CM; Costentin C; Irvine KM; Delamarre A; Lannes A; Sturm N; Oberti F; Patel PJ; Decaens T; Irles-Depé M; Fouchard I; Hermabessière P; Roux M; Barthelon J; Calès P; Powell EE; de Ledinghen V; Boursier J
    Hepatology; 2023 Mar; 77(3):920-930. PubMed ID: 35822302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications.
    Boursier J; Canivet CM; Costentin C; Lannes A; Delamarre A; Sturm N; Le Bail B; Michalak S; Oberti F; Hilleret MN; Irles-Depé M; Fouchard I; Hermabessiere P; Barthelon J; Calès P; Cariou B; de Ledinghen V; Roux M
    Clin Gastroenterol Hepatol; 2023 May; 21(5):1243-1251.e12. PubMed ID: 35288342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores.
    Sanyal AJ; Foucquier J; Younossi ZM; Harrison SA; Newsome PN; Chan WK; Yilmaz Y; De Ledinghen V; Costentin C; Zheng MH; Wai-Sun Wong V; Elkhashab M; Huss RS; Myers RP; Roux M; Labourdette A; Destro M; Fournier-Poizat C; Miette V; Sandrin L; Boursier J
    J Hepatol; 2023 Feb; 78(2):247-259. PubMed ID: 36375686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct comparison of the specialised blood fibrosis tests FibroMeter
    Guillaume M; Moal V; Delabaudiere C; Zuberbuhler F; Robic MA; Lannes A; Metivier S; Oberti F; Gourdy P; Fouchard-Hubert I; Selves J; Michalak S; Peron JM; Cales P; Bureau C; Boursier J
    Aliment Pharmacol Ther; 2019 Dec; 50(11-12):1214-1222. PubMed ID: 31617224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pitfalls in the non-invasive assessment of liver fibrosis with eLIFT-FM
    Wang XC; Zhang XY; Zhang X; Yuan ZX; Li XH; Wang JC; Sun B; Lu XJ
    J Hepatol; 2018 Mar; 68(3):602-603. PubMed ID: 28993184
    [No Abstract]   [Full Text] [Related]  

  • 18. Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis.
    Corpechot C; Gaouar F; El Naggar A; Kemgang A; Wendum D; Poupon R; Carrat F; Chazouillères O
    Gastroenterology; 2014 Apr; 146(4):970-9; quiz e15-6. PubMed ID: 24389304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of a screening algorithm for hepatic fibrosis by Doppler ultrasound and elastography in a general population.
    Renard AS; Paisant A; Cartier V; Calès P; Goyet-Prelipcean M; Geagea E; Tasu JP; Silvain C; Wagner M; Cleach AL; Vilgrain V; Castera L; Bricault I; Decaens T; Savoye-Collet C; Montialoux H; Correas JM; Vallet-Pichard A; Boursier J; Aubé C
    Acta Radiol; 2023 May; 64(5):1730-1737. PubMed ID: 36617943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-Invasive Assessment of Liver Fibrosis Progression and Prognosis in Primary Biliary Cholangitis.
    Poupon R
    Dig Dis; 2015; 33 Suppl 2():115-7. PubMed ID: 26642068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.